Gene & Cell Therapy vs FDA Actions
Side-by-side coverage analysis for Gene & Cell Therapy and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Gene & Cell Therapy
CRISPR, CAR-T, gene editing
- Stories
- 20
- Avg Impact
- 6.2/10
- Dominant Tone
- Neutral
- Latest
- 2d ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Recent Headlines
Gene & Cell Therapy
- Tenaya $0.66 Stock vs $4 Consensus Target: Biotech Risk Signal
- Casgevy Label Expansion and Readouts Could Validate CRISPR's $2.2M Therapy
- Centenarian-Derived SIRT6 Variant's US Patent: 4 Families, 3+ Indications
- 3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57
- uniQure Eyes Q3 2026 Filing for HD Gene Therapy; 4-Year Data in Sept
- ClearPoint Neuro Biologics Revenue Drops 15% in Q2, But New Lab Services Promise Turnaround
- ACROBiosystems PMDA Certificate No. 47 for IL-15 Streamlines Japan Cell & Gene Therapy Trials
- Rznomics' RZ-001 Achieves 0% DLT Rate in Phase 1/2a rGBM Trial, Validating RNA Ribozyme Platform
- UniQure Jumps 78% as FDA Accepts Phase 1/2 Data for AMT-130 BLA
- Casgevy Wins FDA Nod for Kids 2+, Widening $2.2M Gene Therapy Duel
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate